Werewolf Therapeutics, Inc. — Form D/A
Werewolf Therapeutics, Inc. of CAMBRIDGE, MA, a company, filed a Form D amendment with the SEC on 2020-08-13. The offering totals $56.2M, of which $56.2M was reported sold. Industry: Pharmaceuticals.
Offering
- Filed: 2020-08-13
- Form: D/A
- Accession: 0001785530-20-000001
- Industry: Pharmaceuticals
- Exemptions: 06b
- Total offering: $56.2M
- Amount sold: $56.2M
- Investors: 10
- Date of first sale: 2019-08-02
- Security types: equity
- Revenue range: Decline to Disclose
- SEC file number: 021-346661
Issuer
- Name: Werewolf Therapeutics, Inc.
- CIK: 0001785530
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2017
- Address: 1030 MASSACHUSETTS AVENUE, CAMBRIDGE, MA, 02138
- Phone: 617-952-0555
Officers, directors & promoters (11)
| Name | Role | Location |
|---|
| Christoph Westphal | Director | CAMBRIDGE, MA |
| Sakae Asanuma | Director | Cambridge, MA |
| Briggs Morrison | Director | Cambridge, MA |
| Alon Lazarus | Director | Cambridge, MA |
| Derek DiRocco | Director | Boston, MA |
| Luke Evnin | Director | Watertown, MA |
| Elise Wang | Director | Foster City, CA |
| Daniel Hicklin | Director | Cambridge, MA |
| Daniel Hicklin | Executive Officer | Cambridge, MA |
| David Cordo | Executive Officer | Cambridge, MA |
| Patrick Baeuerle | Director | Cambridge, MA |
Other filings by this issuer (2)
More